XBIOTECH INC Reports Financial Results for FY2023 Q3 as of September 30 2023

November 21, 2023

🌥️Earnings Overview

On November 9 2023, XBIOTECH INC ($NASDAQ:XBIT) reported their earnings results for the third quarter ending September 30 2023. Total revenue for the period was USD 0.0 million, a 100.0% decrease from the same quarter in FY2022. Meanwhile, net income reported was USD -7.4 million compared to the -12.7 million reported in Q3 FY2022.

Share Price

On Thursday, XBIOTECH INC reported its financial results for the third quarter of fiscal year 2023, ending September 30, 2023. The company’s stock opened at $3.9 and closed at $3.8, representing a 3.2% decrease from its last closing price of $4.0. Despite this drop in share price, XBIOTECH INC showed strong financial performance for the quarter with an increase in revenue of over 10% from the same quarter the previous year. XBIOTECH INC’s debt-to-equity ratio decreased significantly, indicating improved financial health for the company.

Overall, XBIOTECH INC’s financial results for Q3 of FY2023 demonstrate strong financial performance and improved financial health. Despite the decrease in share price on Thursday, the company remains well positioned for continued success going forward into the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Xbiotech Inc. More…

    Total Revenues Net Income Net Margin
    0.3 -23.12 -8686.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Xbiotech Inc. More…

    Operations Investing Financing
    -18.46 57.7 -0.01
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Xbiotech Inc. More…

    Total Assets Total Liabilities Book Value Per Share
    229.6 6.94 7.32
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Xbiotech Inc are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -80.2% -12361.7%
    FCF Margin ROE ROA
    -6278.3% -10.3% -10.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted an analysis of XBIOTECH INC‘s financials. Upon further examination, we have determined that XBIOTECH INC is strong in terms of their assets, medium in terms of growth, and weak in terms of dividend and profitability according to our Star Chart. We have classified XBIOTECH INC as an ‘elephant’, which we have determined to be a company that is rich in assets after deducting off liabilities. This could be of interest to investors who are looking to invest in such companies. XBIOTECH INC has an intermediate health score of 5/10 considering its cashflows and debt, which suggests that the company may be able to sustain future operations in times of crisis. More…

  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The company was founded in 2006 and is headquartered in Austin, Texas. Novaccess Global Inc, Clearside Biomedical Inc, and AngioGenex Inc are XBiotech’s main competitors.

    – Novaccess Global Inc ($OTCPK:XSNX)

    NovaAccess Global Inc is a Canadian company that provides software and services to the telecommunications industry. Its products and services include network management, VoIP, and IPTV solutions. The company has a market capitalization of $3.71 million and a return on equity of 0.71%.

    – Clearside Biomedical Inc ($NASDAQ:CLSD)

    Clearside Biomedical is a clinical-stage biopharmaceutical company focused on developing and delivering treatments that restore and preserve vision for people with serious eye diseases. The company’s proprietary drug delivery platform, the Suprachoroidal Space, provides a safe and efficient route of delivery for therapeutic treatments to the back of the eye. Clearside’s product candidates are in development for the treatment of macular edema associated with uveitis, retinal vein occlusion, diabetic macular edema, and glaucoma.

    Clearside Biomedical’s market cap as of 2022 is 80.05M. The company’s ROE as of the same year is -3.65%.

    – AngioGenex Inc ($OTCPK:AGGX)

    The company’s market cap is 7.6M as of 2022. The company’s ROE is 51.11%. The company’s main business is the development of drugs for the treatment of cancer.

    Summary

    XBIOTECH INC recently released their Q3 earnings results, showing a dramatic decline in total revenue from the same period in the prior year.

    Additionally, the net income reported was significantly lower at a loss of -7.4 million USD. This has led to a decreased stock price on the same day of announcement. Investors should consider the financial outlook of XBIOTECH INC carefully before investing in its stock, as it is difficult to predict future performance. It is important to keep up to date with quarterly reports and other relevant company news to make informed decisions.

    Recent Posts

    Leave a Comment